Private Sale Round 2 — Now Open

The future of medical cannabis biotech, tokenized on Solana.

Fiberlab Biotech is pioneering cannabis extraction technology and a vertically integrated ecosystem. Own a share of the upside through the $FLI utility token.

Read Whitepaper
$0.25Current FLI Price
$24.6MEcosystem Growth
8,400+Registered Token Holders
SolanaBlockchain
Market Opportunity

A $65B market in motion.

California and Florida together represent the largest legal cannabis markets in the United States. Fiberlab's proprietary Cannapūr® platform addresses extraction yield, purity, and compliance at industrial scale.

$29.4B in 2026 → $64.9B by 2034 at a 21.80% CAGR. Global Medical Cannabis Market Projected value by 2026 Source: Grand View Research
CA Market

$5.3B

Largest regulated medical cannabis market with substantial extraction demand.

FL Growth

$2.0B

Rapidly growing medical cannabis market with increasing patient adoption.

Cannabis Yields

99.9% + Purity

Proprietary extraction technology delivers pharmaceutical-grade output.

Market Opportunity

2026–2030 Medical Cannabis Market Opportunity.

Geographic market progression, tracked on a medical-cannabis-only basis.

California Florida U.S. Europe Global

California

$0.75B

2026

$0.83B

2030

Approx.

State estimate*

Florida

$2.07B

2026

$2.91B

2030

3.9% CAGR

Modeled**

United States

$15.26B

2026

$24.79B

2030

12.9% CAGR

Grand View Research

Europe

$0.47B

2026

$1.27B

2030

27.9% CAGR

Grand View Research

Global

$29.40B

2026

$65.90B

2030

21.8% CAGR

Grand View Research

Five market cards preserve geographic progression without implying that each successive market is larger.

Sources: Grand View Research — U.S. Medical Marijuana Market Size & Outlook; Europe Medical Marijuana Market Size & Outlook; Global Medical Marijuana Market Size & Share Report. *California is an approximate medical-only state estimate from the previously established state-market methodology. **Florida uses the 2026 medical-only run-rate estimate and modeled 2027–2030 growth. State estimates should be identified separately from GVR forecasts.

Regulatory Momentum

Regulatory Momentum.

U.S. federal transition and expanding regulated access across Europe.

United States

Schedule III Transition

  • Federal policy is moving toward greater recognition of regulated medical marijuana products.
  • Qualifying products received Schedule III treatment in April 2026.
  • Broader Schedule I-to-III rescheduling remains under administrative review.
  • Potential benefit: greater support for medical research and market normalization while federal controls remain.
Europe

Expanding Regulated Access

  • Medical cannabis is accommodated through country-specific healthcare, prescription and pharmaceutical frameworks.
  • EU-level rules interact with national medical-cannabis programs; Europe does not operate under one uniform medical-cannabis law.
  • Access is generally controlled through prescribing, pharmacy, quality and diversion-prevention requirements.
  • Germany illustrates the trend: dedicated medical-cannabis regulation alongside tighter prescribing and dispensing oversight.
Investment Context

Medical cannabis is becoming more integrated into regulated healthcare channels in both markets, while governments continue to strengthen prescribing, distribution, quality and oversight requirements.

Sources: U.S. Department of Justice, Office of Public Affairs (Apr. 23, 2026); European Union Drugs Agency (EUDA), Cannabis Laws in Europe FAQ (Apr. 21, 2026); European Drug Report 2026 — Cannabis.

Products

Pharmaceutical-Grade Delivery Systems.

Precision-engineered cannabinoid delivery formats — nasal spray and inhaler — formulated with pure cannabinoids, non-alcohol solutions, and manufactured in GMP-certified facilities.

Cannapūr Rx cannabinoid nasal spray bottle beside its retail carton
Nasal Delivery

Cannabinoid Nasal Spray

Advanced nasal delivery for rapid systemic absorption. No artificial flavors, colors, or preservatives. Ideal for patients requiring fast-onset relief with precise, repeatable dosing.

99.9%+ Pure THC Fast absorption Precision dose per spray No artificial additives GMP certified Eco-friendly formula 10 mL · 100 doses
Cannapūr Rx cannabinoid inhaler beside its retail carton
Inhaled Delivery

Cannabinoid Inhaler

Pulmonary delivery for targeted, fast-acting relief. Delivers pharmaceutical-grade cannabinoids directly to the respiratory system — no combustion, no solvents, no compromise.

99.9%+ Pure THC Pulmonary precision delivery No combustion or solvents No artificial additives GMP certified Eco-friendly design Fast-acting relief
Ecosystem

Three companies. One token.

An integrated stack from molecule to market — research, brand, and distribution unified by $FLI.

$FLI powers the entire stack

FLI

Fiberlab®

Extraction technology company.

Proprietary cannabis extraction systems delivering pharmaceutical-grade cannabinoids at industrial scale with 94% yield efficiency.

KVI

Kannavi™

Consumer health brand.

Bringing cannabinoid formulations to market through innovative consumer packaging and medical delivery formats trusted by patients.

ALX

xAlpha™

Distribution & logistics.

Infrastructure platform handling compliant distribution and logistics across regulated cannabis markets in California and Florida.

Token Utility

Utility, governance, and yield.

$FLI powers every transaction in the Fiberlab ecosystem — from product redemption to governance, staking, and rewards.

  • Governance participation
  • Vote on protocol upgrades
  • Access future investment opportunities
  • Redeem utility within product ecosystem
Tokenomics

Designed for long-term value.

A transparent, community-first token distribution built to align token holders, operators, and the ecosystem.

Ecosystem Rewards
30%
Private Sale
22%
Public Sale
18%
Treasury
12%
Team (4yr vesting)
10%
Liquidity
8%

30M

500M Authorized Total Supply

$2.00

$FLI Token Listing Price

$60M

Market Cap

Current Private Placement

Second Round Offering

August 1 to November 1, 2026

$FLI Tokens
6M
Purchase Price
$0.25
Minimum Investment
$25,000
Total Raise
$1.5M
Roadmap

From private sale to global rollout.

  1. Q3 2026Active

    Private Sale #2

    • Round 2 opens July 2026
    • Minimum investment $1,000
    • Target raise: $52.5M
  2. Q4 2026

    Token Generation

    • $FLI TGE on Solana
    • DEX liquidity provision
    • Staking platform launch
  3. Q1 2027

    Cannabis Product Launch

    • Nasal spray & inhaler retail launch
    • GMP-certified production
    • CA & FL distribution begins
  4. Q3 2027

    DEX Expansion

    • Multi-DEX listing
    • Cross-chain bridging
    • International market entry
Business, Sales and Marketing, Branding and Commercialization Team

Experienced experts in finance, marketing, Healthcare, Law, and Commercialization.

A world class team combining deep biotech science with blockchain expertise and institutional finance

Edward J. Klaeger IV

Founder & CEO

Corporate Finance and Capital Markets.

LinkedIn

Jon Queen

President & Chief Legal Officer

Corporate Law and Investment Banking.

LinkedIn

Bryce Meeker

Chief Business Development Officer

Global Partnerships and Strategic Alliances.

LinkedIn

Natalie Roseth

Co-founder, Managing Director of Global Sales and Marketing

Oncology and Commercialization.

LinkedIn

Samuel M. Kearley

Head of International Sales

International Sales and Expansion.

LinkedIn

Round 2 closes November 1, 2026

Ready to invest in the future of biotech?

Minimum Investment $25,000. Participate in the growth of a vertically-integrated cannabis biotech ecosystem.

FLI Price
$0.25
Token Holders
8,400+
Token Supply
30M
  • Secured on Solana
  • KYC Required
  • Accredited Token Holders Only